Nordic Pharma announced the launch of Nordimet, a new pre-filled auto-injector methotrexate PEN for the treatment of various auto-immune conditions including active rheumatoid arthritis (RA), polyarthritic forms of severe, active juvenile idiopathic arthritis, severe recalcitrant disabling psoriasis and severe psoriatic arthritis.
Nordimet is the first button-free, once-weekly PEN device containing the active substance methotrexate, the most commonly-used Disease Modifying Anti-Rheumatic Drug or DMARD for the treatment of RA.
The announcement is a significant development for both existing and future patients, as the new button-free design removes the need for the patients who may have painful joints to press a button to administer their injection.
Nordimet also has an innovative double-click mechanism that audibly clicks and gently vibrates at the start and at the end of the injection, helping to give patients confidence that their full dose has been administered.
Professor Peter Taylor, Norman Collison Professor of Musculoskeletal Sciences at the University of Oxford and the Head of Clinical Sciences at the Botnar Research Centre commented, ‘The arrival of the new Nordimet, pre-filled and button-free injection device is a most welcome addition to treatment choice for patients requiring parenteral delivery of methotrexate. It enables easy administration, even for patients with severe hand pain or disability with a design that ensures the peace of mind that the full dose has been successfully given.’